Safety analysis of simultaneous integrated boost intensity-modulated radiotherapy with different fractional doses in lung cancer brain metastases(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2021年第4期
- Page:
- 422-425
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- Safety analysis of simultaneous integrated boost intensity-modulated radiotherapy with different fractional doses in lung cancer brain metastases
- Author(s):
- LIU Jine1; SHEN Yongqi1; LIANG Xunsi2; YE Jianzhong3; XIE Huadong4; LIU Wenjian4; LIN Feng1; MENG Jingmin1
- 1. Department of Oncology, Liutie Central Hospital Affiliated to Guangxi Medical University, Liuzhou 545007, China 2. Department of Thoracic Surgery, Longtan Hospital of Guangxi Zhuang Nationality Autonomous Region, Liuzhou 545005, China 3. Department of Oncology, Longtan Hospital of Guangxi Zhuang Nationality Autonomous Region, Liuzhou 545005, China 4. Department of Oncology, Rongshui County Peoples Hospital, Liuzhou 545300, China
- Keywords:
- Keywords: lung cancer brain metastases simultaneous integrated boost intensity-modulated radiotherapy fractional dose safety
- PACS:
- R816.1
- DOI:
- DOI:10.3969/j.issn.1005-202X.2021.04.005
- Abstract:
- Abstract: Objective To discuss the safety of simultaneous integrated boost intensity-modulated radiotherapy with different fractional doses for lung cancer brain metastases, and to analyze the survival rate. Methods Seventy-five patients with brain metastases from lung cancer were selected and randomly divided into 3 groups, and all of them underwent simultaneous integrated boost intensity-modulated radiotherapy. The radiotherapy regimen was the whole brain 40 Gy/20f (2.0 Gy/f) + simultaneous integrated boost to tumor 46 Gy/20f (2.3 Gy/f) in group A, the whole brain 40 Gy/20f (2.0 Gy/f) + simultaneous integrated boost to tumor 52 Gy/20f (2.6 Gy/f) in group B, and the whole brain 40 Gy/20f (2.0 Gy/f) + simultaneous integrated boost to tumor 58 Gy/20f (2.9 Gy/f) in group C. The mean dose and maximum dose delivered to organs-at-risk (eyeball, lens, optic nerve, brain stem), and radiotherapy-induced adverse reactions were compared among 3 groups. After the completion of treatment, all patients underwent regular craniocerebral MRI for evaluating curative effect, and 1-year survival rate was also analyzed. Results The comparison among 3 groups showed that no significant difference was found in the mean dose and maximum dose delivered to organs-at-risk (P>0.05) and the incidence of acute radiotherapy-induced adverse reactions (P>0.05). Moreover, there was no significant difference in the incidence of late neurological adverse reactions (P>0.05). The incidence of radiotherapy-induced adverse reaction of grade 3 was less than 5%, and no radiotherapy-induced adverse reaction occurred. After 1 year of follow-up, the survival rate of group C was higher than that of group A and group B (P<0.05). Conclusion Simultaneous integrated boost intensity-modulated radiotherapy is a safe and effective method for treating brain metastases of lung cancer. With the increase of radiation dose, the curative effect is enhancing.
Last Update: 2021-04-29